Zacks Investment Research downgraded shares of MERRIMACK PHAR (MACK) from NEUTRAL to UNDERPERFORM on March 18, 2013, with a target price of $5.70.
Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MERRIMACK PHAR (MACK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment